OssDsign
-
Biologics
OssDsign awarded long-term agreement with Premier, Inc.
Uppsala, Sweden, April 2 – OssDsign AB (publ.) today announces that the company has been awarded a new group purchasing…
Read More » -
Spine
OssDsign appoints Tom Buckland as Chief Technical Officer
February 29, 2024 – OssDsign AB (publ.) today announces that the company’s current VP of Strategy, Business Development and Regulatory…
Read More » -
Spine
Karolinska Development’s portfolio company OssDsign has received FDA clearance for a new major indication
STOCKHOLM, SWEDEN, September 19, 2023 – Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has received…
Read More » -
Biologics
2,000 patients treated with OssDsign® Catalyst in the U.S.
Uppsala, September 13, 2023. OssDsign AB (publ.) today announces that the company’s orthobiologic business continues to accelerate its successful commercialization…
Read More » -
Spine
OssDsign surpasses 200 patients in its prospective spinal fusion registry PROPEL
Uppsala, August 17, 2023 – OssDsign AB (publ.) today announces that the company has enrolled 200 patients in the multi-center,…
Read More » -
Spine
1,000 patients treated with OssDsign® Catalyst in the U.S.
Uppsala, May 9, 2023 – OssDsign AB (publ.) today announces that 1,000 patients have been treated in the U.S. with…
Read More » -
Spine
Karolinska Development’s portfolio company OssDsign has published a case report from the TOP FUSION study in a scientific journal
STOCKHOLM, SWEDEN, January 4, 2023 – Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has published…
Read More » -
Spine
Karolinska Development’s portfolio company OssDsign completes patient enrollment to the TOP FUSION study
STOCKHOLM, SWEDEN, April 25, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company OssDsign has enrolled…
Read More »